Kato, Yoshinobu Kanaiso Hospital
Kato, Yoshikane Kanaiso Hospital
Matsuzaki, Sayuri Kanaiso Hospital
Waka, Shinnichi Kanaiso Hospital
Ogura, Katsunori Kanaiso Hospital
Degludec and Liraglutide
Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist
Dual Action of Liraglutide and Insulin Degludec
European Xultophy Treatment Retrospective Audit
The patient is a 56-year old (yo) female with type 2 diabetes mellitus (T2DM). Medical histories include persisting T2DM from 35yo, renal stone at 43yo, hypertension from 45yo, photocoagulation for retinopathy on 54yo. An incidentaloma was found in the left adrenal gland, where endocrinological exams were negative for functional tumor. Her diabetic control situation became worse with HbA1c > 10%, then the treatment has been changed from multiple daily injection (MDI), Dulaglutide to Xultophy which is combined agents of degludec and liraglutide (IDegLira). It was provided 10-18 doses daily, and then glucose variability profile was improved satisfactory, suggesting the dual synergistic effects.
Asploro Journal of Biomedical and Clinical Case Reports
This is an open-access article distributed under the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.
asjbccr_4_1_77.pdf 747 KB